05.10.2016 • NewsDede WillamsBASFproduction

BASF Plans new Vitamin A Plant

(c) BASF
(c) BASF

A new plant for vitamin A to be built by BASF at its Ludwigshafen, Germany, main site will increase production capacity by 1,500 t/y, the German group said without disclosing a capacity total.  The facility, planned to support growth at customers, is due on stream in 2020. BASF produces vitamin A both for animal and human nutrition and the cosmetic industry.

Managing board member Michael Heinz said BASF can make “optimal use” of its resources by fully integrating the new production facility into the site’s integrated production system while at the same time enhancing Ludwigshafen’s competitive position.

 

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.